AC Immune and Piramal Imaging announce out-licensing agreement for the development of Tau protein diagnostics in Alzheimer's disease

12.May 2014 08:00 CET

English
Franšais
Deutsch

  • Potential important step towards better diagnosis and clinical management of Alzheimer's disease
  • Tau diagnostics complement AC Immune's therapeutic product pipeline
  • Piramal Imaging initiates Tau-PET-Imaging tracer development program
  • Significant License Agreement signals the importance of the development of Alzheimer's Tau-PET-Imaging tracers